OAC
RLMD icon

OMERS Administration Corp’s Relmada Therapeutics RLMD Stock Holding History

OMERS Administration Corp’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$290K Sell
41,600
-24,300
-37% -$115K ﹤0.01% 865
2025
Q4 		$318K Buy
+65,900
New +$221K ﹤0.01% 793

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OMERS Administration Corp's RLMD Position: Q1 2026 in Review

OMERS Administration Corp reduced its Relmada Therapeutics (RLMD) stake by 37% in Q1 2026, selling an estimated $115K and leaving 41,600 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #865.

OMERS Administration Corp first reported a position in RLMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $318K in Q4 2025. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • OMERS Administration Corp held 41,600 shares of Relmada Therapeutics worth $290K as of Q1 2026.
  • OMERS Administration Corp sold 24,300 Relmada Therapeutics shares in Q1 2026, an estimated $115K.
  • Relmada Therapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #865 holding.
  • OMERS Administration Corp first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Relmada Therapeutics position peaked at $318K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.